Evidence map›Paper›PMID 38750489›Full record

ArticleCancer cell international2024

HPV16-miRNAs exert oncogenic effects through enhancers in human cervical cancer.

Yunuan Wang, Xueying Wang, Yiting Liu, Yuxin He, Xiaoling Duan, Qinmei Li, Yanchun Huang, Guoxiong Xu, Qi Lu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yunuan Wang *Department of Obstetrics and Gynecology, Jinshan Hospital, Fudan University, Shanghai, 201508, China.
Xueying Wang *Shanghai Key Laboratory of Psychotic Disorders, Shanghai Clinical Research Center for Mental Health, Shanghai Institute of Traditional Chinese Medicine for Mental Health, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yiting LiuDepartment of Obstetrics and Gynecology, Jinshan Hospital, Fudan University, Shanghai, 201508, China.
Yuxin HeDepartment of Obstetrics and Gynecology, Jinshan Hospital, Fudan University, Shanghai, 201508, China.
Xiaoling DuanDepartment of Obstetrics and Gynecology, Jinshan Hospital, Fudan University, Shanghai, 201508, China.
Qinmei LiDepartment of Obstetrics and Gynecology, Jinshan Hospital, Fudan University, Shanghai, 201508, China.
Yanchun HuangDepartment of Obstetrics and Gynecology, Jinshan Hospital, Fudan University, Shanghai, 201508, China.
Guoxiong XuResearch Center for Clinical Medicine, Jinshan Hospital, Fudan University, Shanghai, 201508, China.
Qi LuDepartment of Obstetrics and Gynecology, Jinshan Hospital, Fudan University, Shanghai, 201508, China. Dr_Luqi@163.com.

Funding

Major Special Projects of Basic Research of the Science and Technology Commission of Shanghai Municipality 18JC1411104Shanghai Jinshan District Health Special Research Project Fund JSKJ-KTQN-2022-12the Project of the Science and Technology Commission of Shanghai Municipality 20Y11914100the Youth Research Start-up Fund of the Jinshan Hospital, Fudan University JYQN-LC-202101
6 · The paper itself

Abstract

backgroundCervical cancer is a human papillomavirus (HPV)-related disease. HPV type 16 (HPV16), which is the predominant cause of cervical cancer, can encode miRNAs (HPV16-miRNAs). However, the role of HPV16-miRNAs in the pathogenesis of cervical cancer remains unclear.

methodsHuman cervical cancer cell lines SiHa (HPV16-positive) and C33A (HPV-negative), and cervical cancer tissues were collected to investigate the expression levels of two HPV16-miRNAs (HPV16-miR-H1 and HPV16-miR-H6). The overexpression and knockdown of HPV16-miR-H1 and HPV16-miR-H6 were performed using the lentiviral vector system and miRNA inhibitors, respectively. RNA-sequencing (RNA-seq) analysis and H3K27ac chromatin immunoprecipitation and sequencing (CHIP-seq) experiments were utilized to explore the roles of HPV16-miR-H1 and HPV16-miR-H6 facilitated by enhancers. CCK8, EdU, transwell, and wound healing assays were performed to verify the effects of HPV16-miR-H1 and HPV16-miR-H6 on cell proliferation and migration.

resultsHPV16-miR-H1 and HPV16-miR-H6 were highly expressed in both SiHa cells and tissue samples from HPV16-positive cervical cancer patients. RNA-seq analysis showed that HPV16-miR-H1 and HPV16-miR-H6 induced the upregulation of numerous tumor progression-associated genes. H3K27ac CHIP-seq experiments further revealed that HPV16-miR-H1 and HPV16-miR-H6 modulated the expression of critical genes by regulating their enhancer activity. The functional study demonstrated that HPV16-miR-H1 and HPV16-miR-H6 increased the migratory capacity of SiHa cells.

conclusionsOur data shed light on the role of HPV16-encoded miRNAs in cervical cancer, particularly emphasizing their involvement in the miRNA-enhancer-target gene system. This novel regulatory mechanism of HPV16-miRNAs provides new insights and approaches for the development of therapeutic strategies by targeting HPV16-positive cervical cancer.

Indexed as

Cervical cancerEnhancerHPV16-miRNAsHuman papillomavirusVirus-encoded microRNAs

Identifiers

PMID38750489
PMCPMC11097496

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.